Overview
Lumos Pharma is hoping to give a boost to the immune systems of cancer patients. A biopharmaceutical company focused on discovering cancer treatments, Lumos Pharma develops and commercializes small-molecule immunotherapy therapies that stimulate patients' immune systems. The company's leading small-molecule product candidates currently in clinical development target the indoleamine-2, 3-dioxygenase (IDO) pathway, which is one of the key pathways for
...
Read More cancer immune escape. In 2020, Newlink Genetics merged with Lumos Pharma and took its name.
Read Less
Read More cancer immune escape. In 2020, Newlink Genetics merged with Lumos Pharma and took its name.
Read Less
Richard J Hawkins
See more contacts
Scientific Research and Development Services
,
Professional, Scientific, and Technical Services
,
Biological research
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
?
?
?
Modelled
?
Actual
$2.05 million
Actual
34.67%
$40
DEC
?
?
NASDAQ:LUMO
Contacts
Get in Touch with 4 Principals* and 43 Contacts
-
Richard J HawkinsChairman of the Board and Chief Executive Officer
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2023 (12 month period) in USD
Annual Revenue 2023
$2.05 million
USD
Actual
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net Operating Cash | -$31 | -$27 | -$30 |
| Net Investing Cash | $11 | -$11 | $26 |
| Net Financing Cash | -$1 | -$1 | -$0 |
| Net Change in Cash | -$21 | -$39 | -$4 |
| Cash at Beginning of Period | $56 | $95 | $99 |
| Cash at End of Period | $35 | $56 | $95 |
| Capital Expenditure | $ | -$0 | -$0 |
| Assets (mil) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $35 | $56 | $95 |
| Accounts Receivable | $ | $ | $ |
| Inventories | $ | $ | $ |
| Other Current Assets | $5 | $16 | $5 |
| Asset Summary | |||
| Total Current Assets | $40 | $72 | $100 |
| Tangible Fixed Assets | $1 | $0 | $1 |
| Intangible Assets | $ | $ | $ |
| Total Assets | $41 | $72 | $100 |
| Liabilities (mil) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $1 | $0 | $1 |
| Short-Term Debt | $ | $ | $ |
| Other Current Liabilities | $6 | $6 | $5 |
| Liability Summary | |||
| Total Current Liabilities | $7 | $7 | $5 |
| Long-Term Debt | $ | $ | $ |
| Other Long-Term Liabilities | $ | $ | $ |
| Total Liabilities | $13 | $13 | $11 |
| Stakeholder's Equity (mil) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Equity | |||
| Common Stock | $0 | $0 | $0 |
| Retained Earnings | -$162 | -$127 | -$96 |
| Equity Summary | |||
| Total Equity | $27 | $60 | $89 |
| Shares Outstanding | 8,102,555 | 8,267,968 | 8,357,391 |